Publicacións (62) Publicacións de Urbano Anido Herranz

2024

  1. A three-gene expression score for predicting clinical benefit to anti-PD-1 blockade in advanced renal cell carcinoma

    Frontiers in Immunology, Vol. 15

  2. Controversies in prostate cancer management: Consensus recommendations from experts in northern Spain

    Actas Urologicas Espanolas

  3. Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer

    Frontiers in Oncology, Vol. 14

  4. Real-world treatment patterns, survival outcomes, and health care resource utilization for locally advanced or metastatic urothelial carcinoma in Spain

    Clinical and Translational Oncology

2023

  1. Clinical, molecular, and immune correlates of the Immunotherapy Response Score in patients with advanced urothelial carcinoma under atezolizumab monotherapy: analysis of the phase II IMvigor210 trial

    ESMO Open, Vol. 8, Núm. 4

  2. Impact of concurrent tumour events on the prostate cancer outcomes of germline BRCA2 mutation carriers

    European Journal of Cancer, Vol. 185, pp. 105-118

  3. Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study

    Cancers, Vol. 15, Núm. 21

  4. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

2022

  1. Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study

    Clinical Genitourinary Cancer, Vol. 20, Núm. 1, pp. 25-34

  2. Exploring the synergistic effects of cabozantinib and a programmed cell death protein 1 inhibitor in metastatic renal cell carcinoma with machine learning

    Oncotarget, Vol. 13, pp. 237-256

  3. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    European Urology, Vol. 82, Núm. 2, pp. 212-222

  4. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    The Lancet Oncology, Vol. 23, Núm. 3, pp. 362-373

2021

  1. Clinical potential of circulating free DNA and circulating tumour cells in patients with metastatic non-small-cell lung cancer treated with pembrolizumab

    Molecular Oncology, Vol. 15, Núm. 11, pp. 2923-2940

  2. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  3. Epithelial-to-mesenchymal transition mediates resistance to maintenance therapy with vinflunine in advanced urothelial cell carcinoma

    Cancers, Vol. 13, Núm. 24

  4. Longitudinal CTCs gene expression analysis on metastatic castration-resistant prostate cancer patients treated with docetaxel reveals new potential prognosis markers

    Clinical and Experimental Metastasis, Vol. 38, Núm. 2, pp. 239-251

  5. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study

    ESMO open, Vol. 6, Núm. 2, pp. 100090

2020

  1. A new scenario in metastatic renal cell carcinoma: a SOG-GU consensus

    Clinical and Translational Oncology, Vol. 22, Núm. 9, pp. 1565-1579

  2. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

    The Lancet Oncology, Vol. 21, Núm. 12, pp. 1574-1588

  3. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?

    Journal of Chemotherapy, pp. 1-13